Articular cartilage in osteoarthritic patients: efectos of diclofenac, celecoxib and glucosamine sulfate on inflammatory markers
Keywords:
Osteoarthritis, chondrocytes, colagenasa, óxido nítrico, antiinflamatoriosAbstract
Osteoarthritis is a chronic and progressive joint disease. It is established by a complex process involving mechanical and biological alterations of the musculoskeletal system, which are generated by a great variety of interactions between enetic factors and extrinsic injuries. The pathogenesis of this disease is related to an increased and clivergent production of infiammatory markers and proteolytic enzymes that promote the degradation and destruction of the extracellular matrix of articular and periarticular tissues. Cartilage samples were taken frorn 20 osteoarthritic patients during programmed surgical interventions. The cartilage samples were cultu red in Dulbecco-Eagle medium. With or without the addition of SAIDs or modulators of chondrocyte metabolism. The content of nitric oxide in the supernatant was quantified using the Griess reaction: the concentration of MMP- 1 was quantificd vía double-sandwich ELISA. Untreated chondrocyte cultures produced 1950 ± 665ng/ml MMP-1. Wíth the addition of Diclofenac this value decreased to 1140 ± 155 ng/mi, although his difference was not statistically significant (p<0 ,06). However, in the presence of Celecoxib the level significantly dropped to 760 ± 75 ng/mI (p<0,01). Although the addition of glucosarnine did not produce such a noticeable reduction in The level of MMP- 1 (950±89 ng/mi), it was statistically significant (p<0,05). On the contraly, none of the drugs (Diclofenac, Celecoxib, Glucosamine) modified the level of nitric oxide which had a mean value of 47,3 ± 4.911M in the Control samples. This investigation evidenced the inability of Diclofenac to significantly modifr the production of proteolytic enzymes in osteoarthritic chondrocyte cultures. However, both Celecoxib and Glucosamine significantly reduced the production of MMP- 1. On the contrary, none of the drugs used in this study managed to modify the concentration of nitric oxide. To the present day, no drugs have been found to be efficient in altering the natural course of the disease, requiring further investigation
Downloads
References
Loeser RF, Todd MD, Seely BL. Prolonged treatment of human osteoarthritic chondrocytes with insulin-like growth factor-1 stimulates proteoglycan syrithesis but not proteoglycan matrix accumulation in alginate cultures. J Rheumatol 2003 Ju1:30(7):1565-70.
Oliveria SA, Felson DT, Cirillo PA, Reed JI, Walkcr AM. Body weight, body mass index, and incident symptomatic osteoarthritis of the hand, hip, and knee. Epidemiology 1999 Mar: 100:161-6.
Lawrence JS, Bremner JM. Bier F. Osteoarthrosis. Prevalence in the population and relationship between symptoms and x-ray changes. Ann Rheum Dis 1966 Jan;25( 1): 1-24.
Cardiel MH, Rojas-Serrano J. Commuriity based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD study. Clin Exp Rheumatol 2002 Sep:20(5) :617-24.
Anderson JJ, Felson DT. Factors associated with osteoarthritis of the knee in the Iirst national Health and Nutrition Examination Survey (HANES 1). Evidence for an association with overweight, race, and physical demands of work. Am J Epidemiol 1988 Jul:128(1):179-89.
Malemud CJ. Cytokines as therapeutic targets for osteoarthritis. BioDrugs 2004; 18(1):23- 35.
Moo y, Sieper J, Herzog V, Muller BM. Regulation of expression of cytokines and growth factors in osteoarthritic cartilage explants. Clin Rheumatol 2001:20(5):353-8.
S. Abramson SB, Attur M, Amin AR, Clancy R. Nitric oxide and inflammatory mediators in the perpetuation of osteoarthritis. Curr Rheumatol Rep 2001 Dec; 3(6):535-41.
Moncada S, Higgs EA. Endogenous nitric oxide: physiology, pathology and clinical relevance. EurJ Clinlnvest 1991 Aug;21(4):361-74.
Clark IM, Powell LK, Ramsey S, Hazleman BL, Cawston TE. The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluids from patients withosteoarthritis and rheumatoid arthritis. Arthritii Pheum 1993 Mar:36(3):372-9.
Barnes PJ. Molecular biology. Inflammatory activities. Nature 1991 Jan 24:349(6307):2845.
Brandt KD. Insights into the natural history of osteoarthritis provided by the cruciate- eficient dog. An animal model of osteoarthritis. Ann N Y Acad Se¡ 1994 Sep 6:732:199205.
BerenbaumF, GrifkaJ, Brown Zacher J, Moore A, Krammer G, et al. Efficacy of lumiracoxib in osteoarthritis: a review of nine studies. J mt Med Res 2005 Jan;33(1):21-41.
Higgs GA, Moncada S, Vane JR. Eicosanoids in inflammation. Ann Clin Res 1984:16(5-6) -287-99.
Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expressiori of a mitogen- responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc NatiAcad Se¡ USA 1991 Apr 1;88(7):2692-6.
PsatyBM, Furberg CD. COX-21nh1bitors-- lessons in drug saíety. N Engl J Med 2005 Mar 17;352(11):1133-5.
Blot L, Marcelis A, Devogelaer JP, Manicoui-t DH. Effects of diclofenac, aceclofenac and meloxicam en the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br J Pharmacol 2000 Dec;131(7):1413-21.
Chan PS, Caron JP, Rosa GJ, Orth MW. Glucosamine and chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E(2) in articular cartilage explants. Osteoarthritis Cartilage 2005 May; 13(5):387-94.
Dodge GR, Jimenez SA. Glucosamine sulfate modulates the leveis of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthritis Cartilage 2003 Jun: 11(6):424-32.
Nakamura H, Shibakawa A, Tanaka M, Kato T, Nishioka K. Effects of glucosamine hydrochioride ori the production of prostaglandin E2, nitric oxide and metalloproteases by chondrocytes and synoviocytes in osteoarthritis. Clin Exp Rheumatol 2004 May;22(3):2939.
Polisson R. Irinovative therapies in osteoarthritis. Curr Rheumatol Rep 2001
I)ec:3(6):489-95.
Poolsup N, Suthisisang C. Channark P. Kittikulsuth W. Glucosamine long-term treatment and the progression of kneeosteoarthritis: systematic review of rand omized controlled trials. Arin Pharmacother 2005 Jun:39(6): 1080-7.
Schurman DJ, Smith RL. Osteoarthritis: current treatment and future prospects for surgical, medical, and biologic intervention. Clin Orthop Relat Res 2004 Oct;(427 Suppl):S 183-
S189.
Altman R, Asch E, Bloch D, Bole G. Borenstein D, Brandt K, et al. Development of entena for the classifieation and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986 Aug:29(8): 1039-49.
Green LC, Wagner DA, Glogowski J. Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite. and [15Njnitrate in biological fluids. Anal Biochem 1982 Oct: 126(1):131-8.
Cortas NK, Wakid NW. Determination of inorganic nitrate in serum and unne by a kinetic cadmium-reduction method. Clin Chem 1990 Aug:36(8Pt 1):1440-3.
Montrull HL, Brizuela NY, Demurtas SL, Spitale L, Meirovich CI. Structure and secretory activity of cultured chondrocytes from patients with osteoarthritis. Biocell 2005 Aug:29(2): 163-7.
Martel-PelletierJ, McCollum R, Fujimoto N, Obata K. CloutierJM, PelletierJP. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest 1994 Jun:70(6) :807-15.
Monfort J, Garcia-Giralt N. Lopez- Armada MJ, Monliau JC, Bonilla A. Benito P, et al. Decreased metalloproteinase production as a response to mechanical pressure in human cartilage: a mechanism for horneostatic regulation. Arthritis Res Ther 2006;8(5):R 149.
Emery P. Clinical implications of selective cyclooxygenase-2 inhibition. Scand J heumatol Suppl 1996:102:23-8.
Vuolteenaho K, Moilanen T, Hamalainen M. Moilanen E. Regulation of nitric oxide production in osteoarthritic and rheumatoid cartilage. Role of endogenous IL- 1 inhibitors. ScandJ Rheumatol 2003:32(1):19-24.
Downloads
Published
Issue
Section
License
Copyright (c) 2019 Universidad Nacional de Córdoba
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The generation of derivative works is allowed as long as it is not done for commercial purposes. The original work may not be used for commercial purposes.
